Sophia Genetics SA (SOPH) - Total Assets
Based on the latest financial reports, Sophia Genetics SA (SOPH) holds total assets worth $163.46 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Sophia Genetics SA for net asset value and shareholders' equity analysis.
Sophia Genetics SA - Total Assets Trend (2018–2024)
This chart illustrates how Sophia Genetics SA's total assets have evolved over time, based on quarterly financial data.
Sophia Genetics SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Sophia Genetics SA's total assets of $163.46 Million consist of 64.0% current assets and 36.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 51.7% |
| Accounts Receivable | $8.69 Million | 5.6% |
| Inventory | $5.87 Million | 3.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $20.66 Million | 13.3% |
| Goodwill | $8.34 Million | 5.4% |
Asset Composition Trend (2018–2024)
This chart illustrates how Sophia Genetics SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Sophia Genetics SA (SOPH) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sophia Genetics SA's current assets represent 64.0% of total assets in 2024, a decrease from 81.9% in 2018.
- Cash Position: Cash and equivalents constituted 51.7% of total assets in 2024, down from 70.4% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, an increase from 11.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 13.3% of total assets.
Sophia Genetics SA Competitors by Total Assets
Key competitors of Sophia Genetics SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Alcidion Group Ltd
AU:ALC
|
Australia | AU$115.63 Million |
|
DocCheck AG
XETRA:AJ91
|
Germany | €53.98 Million |
|
TRELLUS HEALTH LS -0006
F:85Q
|
Germany | €9.22 Million |
|
Pro Medicus Ltd
AU:PME
|
Australia | AU$533.91 Million |
|
Echoiq Ltd
AU:EIQ
|
Australia | AU$17.99 Million |
|
ARTRYA Ltd
AU:AYA
|
Australia | AU$23.68 Million |
|
Cogstate Ltd
AU:CGS
|
Australia | AU$64.77 Million |
|
Oneview Healthcare Plc
AU:ONE
|
Australia | AU$15.49 Million |
Sophia Genetics SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.80 | 3.80 | 5.08 |
| Quick Ratio | 2.62 | 3.59 | 4.92 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $66.55 Million | $86.34 Million | $88.11 Million |
Sophia Genetics SA - Advanced Valuation Insights
This section examines the relationship between Sophia Genetics SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.32 |
| Latest Market Cap to Assets Ratio | 2.07 |
| Asset Growth Rate (YoY) | -24.7% |
| Total Assets | $155.31 Million |
| Market Capitalization | $321.60 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Sophia Genetics SA's assets at a significant premium (2.07x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Sophia Genetics SA's assets decreased by 24.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sophia Genetics SA (2018–2024)
The table below shows the annual total assets of Sophia Genetics SA from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $155.31 Million | -24.66% |
| 2023-12-31 | $206.16 Million | -15.45% |
| 2022-12-31 | $243.84 Million | -23.84% |
| 2021-12-31 | $320.17 Million | +142.34% |
| 2020-12-31 | $132.12 Million | +155.76% |
| 2019-12-31 | $51.66 Million | -32.58% |
| 2018-12-31 | $76.62 Million | -- |
About Sophia Genetics SA
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutic… Read more